Also Read: Indias anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales Also, the fact that prescription growth has flattened suggests retention and patient continuation are not yet where the industry expected them to be, said Kovil
Scripps Clinic obesity and internal medicine specialist Mitch Biermann, MD, PhD, and Scripps Clinic internal medicine resident Michelle Wong, MD, report in the medical journal Obesity that most participants in their small clinical study sustained their peak weight loss from the popular medications even after reducing the dose frequency to once every two weeks and, for some patients, as infrequently as once every six weeks
BENEFITS OF GROWTH HORMONE STIMULATING PEPTIDE THERAPY (SEMORELIN/IPAMORELIN CJC1295 OR COMBINATION) Growth Hormone Stimulation/Peptide Therapy (Sermorelin, Ipamorelin-CJC1295) helps encourage the production of HGH, testosterone and other hormones
GLP-1s also help reduce disordered eating including reduced emotional eating, less eating in response to external triggers, less binge eating, loss-of-control eating and food rumination
This work was supported by the Wilmot Cancer Institute Predoctoral Fellowship (G.A.), Wilmot Cancer Institute Pilot Funding (I.S.H.), the American Association for Cancer Research and Breast Cancer Research Foundation (20-20-26-HARR) (I.S.H.), Breast Cancer Coalition of Rochester (I.S.H.), a Sir Henry Wellcome Postdoctoral Fellowship (M.E.K.), and a FNR-CORE grant C21/BM/15796788 (D.B.), and NIH grants R01CA269813 (I.S.H.), R37CA230042 (G.M.D), R24AA022057 (V.V.), R01AA028859 (Y.C.), AI150698 (J.M.), K01CA240533-01A1 (C.L.C.), and R01AR078000 (R.T.D.)